Ieq Capital, LLC Mirati Therapeutics, Inc. Transaction History

Ieq Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 03, 2023	SELL	$27.8 - $45.35 $222 - $362	-8 Reduced 0.06%	12,615 $549,000
Q2 2023 Aug 07, 2023	BUY	$36.13 - $49.49 $289 - $395	8 Added 0.06%	12,623 $456,000
Q4 2022 Feb 03, 2023	SELL	$41.27 - $98.62 $247 - $591	-6 Reduced 0.05%	12,615 $571,000
Q3 2022 Nov 03, 2022	BUY	$59.5 - $86.7 $357 - $520	6 Added 0.05%	12,621 $881,000
Q2 2022 Jul 27, 2022	SELL	$39.16 - $88.71 $352 - $798	-9 Reduced 0.07%	12,615 $847,000
Q1 2022 Apr 26, 2022	BUY	$75.82 - $150.97 $682 - $1,358	9 Added 0.07%	12,624 $1.04 Million
Q4 2021 Jan 31, 2022	SELL	$132.01 - $190.29 $30,890 - $44,527	-234 Reduced 1.82%	12,615 $1.85 Million
Q3 2021 Nov 09, 2021	BUY	$132.13 - $177.45 $1.7 Million - $2.28 Million	12,849 New	12,849 $2.27 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Ieq Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ieq Capital, LLC with notifications on news.